全文获取类型
收费全文 | 52335篇 |
免费 | 4228篇 |
国内免费 | 1584篇 |
专业分类
耳鼻咽喉 | 617篇 |
儿科学 | 634篇 |
妇产科学 | 1086篇 |
基础医学 | 8148篇 |
口腔科学 | 1412篇 |
临床医学 | 4356篇 |
内科学 | 10008篇 |
皮肤病学 | 1002篇 |
神经病学 | 3759篇 |
特种医学 | 1692篇 |
外国民族医学 | 6篇 |
外科学 | 7305篇 |
综合类 | 3969篇 |
现状与发展 | 1篇 |
一般理论 | 5篇 |
预防医学 | 2958篇 |
眼科学 | 1376篇 |
药学 | 4713篇 |
中国医学 | 755篇 |
肿瘤学 | 4345篇 |
出版年
2023年 | 196篇 |
2022年 | 317篇 |
2021年 | 546篇 |
2020年 | 348篇 |
2019年 | 624篇 |
2018年 | 1126篇 |
2017年 | 869篇 |
2016年 | 862篇 |
2015年 | 967篇 |
2014年 | 1280篇 |
2013年 | 1578篇 |
2012年 | 2146篇 |
2011年 | 2081篇 |
2010年 | 1252篇 |
2009年 | 1235篇 |
2008年 | 1841篇 |
2007年 | 1950篇 |
2006年 | 1813篇 |
2005年 | 1489篇 |
2004年 | 1356篇 |
2003年 | 1327篇 |
2002年 | 1258篇 |
2001年 | 4630篇 |
2000年 | 4541篇 |
1999年 | 3905篇 |
1998年 | 1374篇 |
1997年 | 998篇 |
1996年 | 607篇 |
1995年 | 501篇 |
1994年 | 449篇 |
1993年 | 412篇 |
1992年 | 1931篇 |
1991年 | 1674篇 |
1990年 | 1527篇 |
1989年 | 1488篇 |
1988年 | 1296篇 |
1987年 | 1190篇 |
1986年 | 1063篇 |
1985年 | 899篇 |
1984年 | 588篇 |
1983年 | 467篇 |
1982年 | 249篇 |
1981年 | 180篇 |
1980年 | 141篇 |
1979年 | 280篇 |
1978年 | 77篇 |
1974年 | 75篇 |
1973年 | 95篇 |
1972年 | 71篇 |
1969年 | 66篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Parallel enzyme‐linked immunosorbent assay screening for human immunodeficiency virus among blood donors in five Chinese blood centres: a retrospective analysis 下载免费PDF全文
3.
4.
5.
Emmi Helle Aldo Córdova-Palomera Tiina Ojala Priyanka Saha Praneetha Potiny Stefan Gustafsson Erik Ingelsson Michael Bamshad Deborah Nickerson Jessica X. Chong University of Washington Center for Mendelian Genomics Euan Ashley James R. Priest 《Genetic epidemiology》2019,43(2):215-226
Loss of function variants in NOTCH1 cause left ventricular outflow tract obstructive defects (LVOTO). However, the risk conferred by rare and noncoding variants in NOTCH1 for LVOTO remains largely uncharacterized. In a cohort of 49 families affected by hypoplastic left heart syndrome, a severe form of LVOTO, we discovered predicted loss of function NOTCH1 variants in 6% of individuals. Rare or low-frequency missense variants were found in 16% of families. To make a quantitative estimate of the genetic risk posed by variants in NOTCH1 for LVOTO, we studied associations of 400 coding and noncoding variants in NOTCH1 in 1,085 cases and 332,788 controls from the UK Biobank. Two rare intronic variants in strong linkage disequilibrium displayed significant association with risk for LVOTO amongst European-ancestry individuals. This result was replicated in an independent analysis of 210 cases and 68,762 controls of non-European and mixed ancestry. In conclusion, carrying rare predicted loss of function variants in NOTCH1 confer significant risk for LVOTO. In addition, the two intronic variants seem to be associated with an increased risk for these defects. Our approach demonstrates the utility of population-based data sets in quantifying the specific risk of individual variants for disease-related phenotypes. 相似文献
6.
7.
J Phua E S C Koay D Zhang L K Tai X L Boo K C Lim T K Lim 《The European respiratory journal》2006,28(4):695-702
Levels of the soluble form of the triggering receptor expressed on myeloid cells (sTREM)-1 are elevated in severe sepsis. However, it is not known whether sTREM-1 measurements can distinguish milder bacterial infections from noninfectious inflammation. The present authors studied whether serum sTREM-1 levels differ in community-acquired pneumonia, exacerbations of chronic obstructive pulmonary disease (COPD), asthma and controls, and whether sTREM-1 may be used as a surrogate marker for the need for antibiotics. Serum sTREM-1 levels in 150 patients with pneumonia, COPD and asthma exacerbations and 62 healthy controls were measured. Serum sTREM-1 levels were significantly elevated in pneumonia (median 295.2 ng x mL(-1)), COPD (280.3 ng x mL(-1)) and asthma exacerbations (184.0 ng x mL(-1)) compared with controls (83.1 ng x mL(-1)). Levels were higher in pneumonia and Anthonisen type 1 COPD exacerbations than in type 2 and 3 COPD and asthma exacerbations. The area under the receiver operating characteristics curve for sTREM-1 as a surrogate marker for the need for antibiotics was 0.77. Serum levels of the soluble form of the triggering receptor expressed on myeloid cells-1 were elevated predominantly in pneumonia and Anthonisen type 1 COPD exacerbations versus type 2 and 3 chronic obstructive pulmonary disease exacerbations, asthma and controls. Serum levels of the soluble form of the triggering receptor expressed on myeloid cells-1 has moderate but insufficient accuracy as a surrogate marker for the need for antibiotics in lower respiratory tract infections. 相似文献
8.
9.
A. HAZIOT I. KATZ G. W. RONG X. Y. LIN J. SILVER & S. M. GOYERT 《Scandinavian journal of immunology》1997,46(3):242-245
Membrane-bound CD14 acts as a receptor for lipopolysaccharide (LPS) on monocytes/macrophages and neutrophils. Studies have suggested that the activation of monocytes/macrophages by the binding of LPS to membrane-bound CD14 may require the association of a signal-transducing molecule with membrane-bound CD14. The observation that non-CD14 expressing cells, such as endothelial cells, can nevertheless be activated by a complex of LPS and a soluble form of CD14 (sCD14) suggests that the receptor for this complex may be identical to the signal transducing molecule associated with membrane-bound CD14. The studies described show that two CD14-specific MoAb are able to block the LPS-induced activation of endothelial cells but do not affect the response of monocytes to LPS. This suggests that the interaction of the sCD14:LPS complex with endothelial cells is distinct from the interaction of membrane-bound CD14 with its putative signal-transducing molecule. 相似文献
10.
Plasmid DNA encoding transforming growth factor-beta1 suppresses chronic disease in a streptococcal cell wall-induced arthritis model. 总被引:6,自引:0,他引:6 下载免费PDF全文
X Y Song M Gu W W Jin D M Klinman S M Wahl 《The Journal of clinical investigation》1998,101(12):2615-2621
Transforming growth factor beta is a potent immunomodulator with both pro- and antiinflammatory activities. Based on its immunosuppressive actions, exogenous TGF-beta has been shown to inhibit autoimmune and chronic inflammatory diseases. To further explore the potential therapeutic role of TGF-beta, we administered a plasmid DNA encoding human TGF-beta1 intramuscularly to rats with streptococcal cell wall-induced arthritis. A single dose of 300 microg plasmid DNA encoding TGF-beta1, but not vector DNA, administered at the peak of the acute phase profoundly suppressed the subsequent evolution of chronic erosive disease typified by disabling joint swelling and deformity (articular index = 8.17+/-0. 17 vs. 1.25+/-0.76, n = 6, day 26, P < 0.01). Moreover, delivery of the TGF-beta1 DNA even as the chronic phase commenced virtually eliminated subsequent inflammation and arthritis. Both radiologic and histopathologic as well as molecular evidence supported the marked inhibitory effect of TGF-beta1 DNA on synovial pathology, with decreases in the inflammatory cell infiltration, pannus formation, cartilage and bone destruction, and the expression of proinflammatory cytokines that characterize this model. Increases in TGF-beta1 protein were detected in the circulation of TGF-beta1 DNA-treated animals, consistent with the observed therapeutic effects being TGF-beta1 dependent. These observations provide the first evidence that gene transfer of plasmid DNA encoding TGF-beta1 provides a mechanism to deliver this potent cytokine that effectively suppresses ongoing inflammatory pathology in arthritis. 相似文献